Comparative study for mucosal concentration of 5-ASA by once-daily vs divided dosing of oral mesalazine in quiescent ulcerative colitis

Comparative study for mucosal concentration of 5-ASA by once-daily vs divided dosing of oral mesalazine in quiescent ulcerative colitis - Mucosal concentration of 5-ASA by once-daily vs conventional dosing

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010127

Enrollment

Registered

2013-04-01

Start date

2013-09-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

Eligible patients will be treated with 3g of oral mesalazine once daily for at least two weeks Eligible patients will be treated with 3g of oral mesalazine twice daily for at least two weeks Eligible

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Outpatients 2) Adult patients who have been in remission by the treatment with oral mesalazine 3) Patients who able provided written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with severe active or fulminant ulcerative colitis 2) Patients who received total or subtotal colectomy 3) Patients with malignancy 4) Patients who are pregnant or have the possibility of pregnancy 5) Patients whom investigators and subinvestigators considered to be inappropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
Mucosal concentration of 5-ASA in the Rectum	—

Secondary

Measure	Time frame
Mucosal concentration of Ac-5-ASA in the rectum	—

Countries

Japan

Contacts

Public ContactMinoru Matsuura

Kyoto University Hospital Department of Gastroenterology and Hepatology

minomats@kuhp.kyoto-u.ac.jp075-751-4319

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026